Results 141 to 150 of about 6,822 (175)
[An overview of home care for patients with chronic diseases in Latin America: A scoping reviewPanorama da atenção domiciliar para pacientes com doenças crônicas na América Latina: revisão de escopo]. [PDF]
Fonseca Valencia C +5 more
europepmc +1 more source
[Substandard and falsified medical products: 25 years of successful network collaboration among regulatory authorities in the AmericasProdutos médicos de qualidade inferior e falsificados: 25 anos de colaboração bem-sucedida em rede entre autoridades reguladoras da Região das Américas]. [PDF]
Vahos Zambrano J +9 more
europepmc +1 more source
[Stigma and acceptance of telemedicine in rural Peruvian mental health]. [PDF]
Rodríguez Eguizabal JL.
europepmc +1 more source
[Ethical and conceptual considerations in telemedicine: A necessary reflection]. [PDF]
Rives Rovira R, Planes Olives C.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Riesgos de seguridad de los datos en la web
Journal TechInnovation, 2022En el mundo actual, la información y los datos son un activo valioso para cualquier organización. Sin embargo, con el aumento del uso de la tecnología y la dependencia de internet, los riesgos de seguridad de los datos en la web se han vuelto cada vez más preocupantes. Los ataques cibernéticos, el robo de identidad, y la pérdida de datos confidenciales
Geanfrank Isaias Cruz Lucas +3 more
openaire +1 more source
Medicina Clínica, 2016
The main effect of SGLT2 inhibitors is their glycosuric action. These drugs reverse the deleterious effect of increased glucose reabsorption by the renal tubule in persons with DM2. In terms of efficacy, SGLT2 inhibitors produce a mean HbA1c reduction of 0.8%, although higher initial HbA1c levels can show a larger decrease.
Pablo Gómez-Fernandez
exaly +2 more sources
The main effect of SGLT2 inhibitors is their glycosuric action. These drugs reverse the deleterious effect of increased glucose reabsorption by the renal tubule in persons with DM2. In terms of efficacy, SGLT2 inhibitors produce a mean HbA1c reduction of 0.8%, although higher initial HbA1c levels can show a larger decrease.
Pablo Gómez-Fernandez
exaly +2 more sources

